Translating into Español. The English version is shown until it is ready.
China health experts urge problem-driven push to turn disease research into treatments
En breve
Experts at a 2026 conference on disease prevention research and translation in China called for problem-driven collaboration between hospitals, universities and industry, with AI among the topics discussed. The director of a national key laboratory said the platform had recorded six innovative drug technology exports and had funded more than 500 projects across 344 institutions. The president of Shenyang Pharmaceutical University said the main bottleneck is pilot-scale production, moving from milligram to kilogram quantities.
Leer la noticia completa 3 min de lectura
A 2026 conference on collaborative innovation in disease prevention research and translation was held, co-hosted by the National Health Commission’s Medical Science and Technology Development Research Center, Health News and the National Key Laboratory for Neuroscience and Oncology Drug R&D, China News Service reported on October 5. Academicians and experts discussed open sharing between industry, academia, research and hospitals, and coordination between AI and multidisciplinary diagnosis and treatment. The document does not say where the meeting took place. [ 1 ]
Gu Ning, a Chinese Academy of Sciences academician and Nanjing University professor, said the blood circulation system is closely linked to the nervous and immune systems, so treatment and prevention of cardiovascular disease need to be considered as a whole. Nanomedicine, built on fast-developing nanocarriers, can make treatment more precise, efficient and safe, he said, and should keep working on the clinical difficulty that cardiovascular disease is hard to detect early. Gu Jinhui, party secretary and director of the health commission’s research centre, said the 15th Five-Year Plan period should give more play to sci-tech innovation in developing what he called health new quality productive forces, by strengthening coordination of research, improving the innovation system and optimising the translation ecosystem. [ 1 ]
Tang Renhong, director of the National Key Laboratory for Neuroscience and Oncology Drug R&D, said the platform aims to develop original drugs and solve clinical pain points while building an open innovation ecosystem. He said it has achieved six innovative drug technology exports, and that its programmes have funded more than 500 projects across 344 institutions in five disciplines. Next, he said, the laboratory will work with other parties to build a government-industry-research-hospital innovation ecosystem. [ 1 ]
AI was one focus of the discussion. Wang Cunyu, dean of Peking University’s Institute for Advanced Clinical Medicine, said tumours are highly complex and long-term management as a chronic disease still faces many challenges, but recent progress such as tumour immunotherapy shows further possibilities; AI and other new technologies, he said, offer new ways to understand tumours and explore treatment strategies. Wang Guangji, a Chinese Academy of Engineering academician and China Pharmaceutical University professor, said pharmaceutical innovation should start from patients’ unmet medical needs, break down boundaries between disciplines, institutions and industries, and focus research on neurodegenerative diseases and malignant tumours. [ 1 ]
Qi Lianwen, president of Shenyang Pharmaceutical University, said the translation chain must be problem-oriented rather than paper-oriented, with problems coming from clinical practice and industry demand. He said a major bottleneck is pilot-scale production: many studies struggle to go from drug to product, and harder still to a marketable good, mainly because large-scale production from milligram to kilogram quantities is difficult. Universities need to build pilot platforms in an organised way and push through key steps such as clinical approvals, he said, adding that hospitals and industry should be involved early rather than buying results after they are finished. Innovative drug development is a long process, he said, requiring sustained effort and tolerance of failure. [ 1 ]
Xinhua’s feed carried an item titled “成果” at 23:50 with no summary or article text, so its content cannot be verified and it is not established that it refers to the same conference. The remaining document, from cnBeta, was about a live-action Street Fighter film and is unrelated to this event. [ 2 , 3 ]
Por qué importa
The meeting sets out the direction several universities, academicians and the health ministry’s research centre want for Chinese medical research, from giving more play to sci-tech innovation in the next five-year plan to building pilot-scale manufacturing capacity. The bottlenecks named — pilot production and the gap between a research result and a marketable product — are the practical constraints on turning Chinese drug research into treatments. Because the only detailed account comes from one official outlet, no decisions or follow-up commitments from the meeting are known.
Datos clave
- A 2026 conference on collaborative innovation in disease prevention research and translation was held, co-hosted by the National Health Commission’s Medical Science and Technology Development Research Center, Health News and the National Key Laboratory for Neuroscience and Oncology Drug R&D. [ 1 ]
- Gu Ning, a Chinese Academy of Sciences academician and Nanjing University professor, said nanomedicine could make treatment more precise, efficient and safe and should focus on the clinical difficulty that cardiovascular disease is hard to detect early. [ 1 ]
- Gu Jinhui, party secretary and director of the health commission’s research centre, said the 15th Five-Year Plan period should give more play to sci-tech innovation, with stronger coordination of research, a better innovation system and an improved translation ecosystem. [ 1 ]
- Tang Renhong, director of the National Key Laboratory for Neuroscience and Oncology Drug R&D, said the platform has achieved six innovative drug technology exports and has funded more than 500 projects covering 344 institutions. [ 1 ]
- Wang Cunyu, dean of Peking University’s Institute for Advanced Clinical Medicine, said AI and other new technologies offer new ways to understand tumours and explore treatment strategies. [ 1 ]
- Wang Guangji, a Chinese Academy of Engineering academician and China Pharmaceutical University professor, said drug innovation should start from patients’ unmet medical needs and break down boundaries between disciplines, institutions and industries. [ 1 ]
- Qi Lianwen, president of Shenyang Pharmaceutical University, said translation must be problem-oriented rather than paper-oriented, and that pilot-scale production from milligram to kilogram quantities is a key bottleneck. [ 1 ]
Confirmado por varias fuentes
- A 2026 conference on collaborative innovation in disease prevention research and translation was held, co-hosted by the National Health Commission’s Medical Science and Technology Development Research Center, Health News and the National Key Laboratory for Neuroscience and Oncology Drug R&D. [ 1 ]
- Speakers at the conference called for integrating industry, academia, research and hospitals, and discussed open sharing and coordination between AI and multidisciplinary diagnosis and treatment. [ 1 ]
- The National Key Laboratory for Neuroscience and Oncology Drug R&D is building an open innovation ecosystem and aims to develop original drugs addressing clinical pain points, its director said. [ 1 ]
- Qi Lianwen, president of Shenyang Pharmaceutical University, said the main bottleneck in translation is pilot-scale production, moving from milligram to kilogram quantities. [ 1 ]
Aún sin aclarar
- The city where the conference was held. The document does not state the location of the meeting.
- Whether the Xinhua feed item titled “成果” refers to the same conference, and what it reported. The Xinhua item carried only a one-word headline with no summary or article text, and no other document links it to the meeting.
- The exact dates of the conference, the number of participants and any decisions or follow-up commitments. The documents do not state these details.
- Whether the reported research progress and the figures on technology exports and funded projects have been independently reviewed or published. The figures come from the laboratory’s director as quoted by a single outlet.